No Recovery, No Fee. Free Consultation.

LaGuardia Runway Collision between Air Canada Jet & Fire Truck Learn more →

Case
Pharmaceutical & Medical Injury

Successful Settlement of Claims Relating to GranuFlo NaturaLyte Litigation

Attorneys

The MDL and Massachusetts State Plaintiffs Steering Committees are pleased to announce an agreement in principle to resolve all state and federal litigation involving claims relating to the use of GranuFlo and NaturaLyte by dialysis patients for $250 million. 

Plaintiff’s decedent suffered a cardiac event and died as a result of use of defendants’ defective product during dialysis.
~ Kreindler Lawsuit

The terms of the settlement, which are based on a mediator's recommendation, requires approval by July 2016. Plaintiffs' leadership expects the settlement funds to be allocated to eligible plaintiffs based on relevant facts particular to their individual cases. The process will be ongoing over the next several months.

Anthony Tarricone
Liaison Counsel
Plaintiffs Executive Committee
In Re GranuFlo/NaturaLyte Products Liability Litigation
MDL No. 1:13-MD-2428-DPW

In the Media

Successful Settlement of Claims Relating to GranuFlo NaturaLyte Litigation

A New York Times article written by Andrew Pollock discusses the settlement made by Fresenus Medical Care, the world’s largest provider of kidney dialysis equipment and services. The agreement to pay $250 million will settle thousands of lawsuits.

GranuFlo Heart Attack Investigation

The FDA ordered a Class 1 recall of Fresenius' Naturalyte liquid and Granuflo dry acid concentrate due to extreme heart attack risk.

Kreindler worked on behalf of patients or families injured after being administered Fresenius' Naturalyte liquid and GranuFlo dry acid concentrate during dialysis. 

The government found that these drugs are unsafe and can cause:

<ul><li>Cardiopulmonary arrest &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br></li><li>Low blood pressure&nbsp;<br></li><li>Hypokalemia &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul>

<ul><li>Hypoxemia &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<br></li><li>Hypercapnia &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li></ul>

<ul><li>Cardiac arrhythmia &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<br></li><li>Death</li></ul>

Investigation has disclosed that Fresenius Medical Care North America, based in Waltham, Massachusetts, knew its product posed a serious risk of injury and death for certain identifiable dialysis patients. Fresenius Medical Care failed to disclose this critical information to the government or health care providers, which allowed continued high dose administration of the drug in high risk patients and led to avoidable injury and death. 

Fresenius Medical Care is the largest operator of hemodialysis clinics in the United States. It is also a leading supplier of dialysis machines and dialysis supplies. There is evidence that information about dosage risk was given to Fresenius-operated clinics but was withheld from other clinics using its GranuFlo and Naturalyte products. The company is currently being investigated for failing to inform consumers of the risks connected to excessive doses of its dialysis products.